ADAPTIS
GenericsADAPTIS is a generic drug manufacturer focused on Neurology, Oncology, Cardiovascular.
ADAPTIS's Key Drugs
ADAPTIS's core commercial portfolio centers on DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, spanning Neurology and Oncology — its most strategically important drugs approved in the last 15 years.
ADAPTIS's Recent FDA Approvals
New NDA/BLA approvals for ADAPTIS over the last two years — novel drugs only, excluding generics and label supplements.
ADAPTIS's Therapeutic Areas
ADAPTIS's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ADAPTIS's Top Competitors
ADAPTIS's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ADAPTIS Pipeline Snapshot
Active clinical trials for ADAPTIS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (1)
Company Info
- First Approval
- 1994-06-30
- Latest
- 2026-11-02
- Applications
- 71